Autolus Therapeutics plc (NASDAQ:AUTL) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC decreased its position in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 64.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 67,329 shares of the company's stock after selling 121,911 shares during the period. SG Americas Securities LLC's holdings in Autolus Therapeutics were worth $244,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Avoro Capital Advisors LLC acquired a new position in Autolus Therapeutics during the first quarter worth $78,765,000. Price T Rowe Associates Inc. MD raised its position in shares of Autolus Therapeutics by 82.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company's stock worth $35,020,000 after purchasing an additional 2,487,778 shares during the last quarter. Great Point Partners LLC lifted its stake in Autolus Therapeutics by 195.0% in the 2nd quarter. Great Point Partners LLC now owns 3,441,667 shares of the company's stock valued at $11,977,000 after buying an additional 2,275,000 shares in the last quarter. Affinity Asset Advisors LLC lifted its stake in Autolus Therapeutics by 117.7% in the 1st quarter. Affinity Asset Advisors LLC now owns 3,375,000 shares of the company's stock valued at $21,532,000 after buying an additional 1,824,592 shares in the last quarter. Finally, Armistice Capital LLC boosted its holdings in Autolus Therapeutics by 33.8% in the 2nd quarter. Armistice Capital LLC now owns 6,250,000 shares of the company's stock worth $21,750,000 after buying an additional 1,578,000 shares during the last quarter. Institutional investors and hedge funds own 72.83% of the company's stock.

Autolus Therapeutics Price Performance

Shares of Autolus Therapeutics stock traded down $0.08 during mid-day trading on Tuesday, reaching $4.44. 1,011,083 shares of the stock traded hands, compared to its average volume of 1,353,629. The stock has a market capitalization of $1.18 billion, a PE ratio of -3.77 and a beta of 2.04. The business has a 50-day moving average of $3.96 and a 200 day moving average of $4.10. Autolus Therapeutics plc has a fifty-two week low of $2.21 and a fifty-two week high of $7.45. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.09.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). On average, analysts predict that Autolus Therapeutics plc will post -0.84 EPS for the current year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.